Document is current
Any future updates will be listed below
-
Authors
Ugai, Tomotaka
Väyrynen, Juha P.
Lau, Mai Chan
Borowsky, Jennifer
Akimoto, Naohiko
Väyrynen, Sara A.
Zhao, Melissa
Zhong, Rong
Haruki, Koichiro
Dias Costa, Andressa
Fujiyoshi, Kenji
Arima, Kota
Wu, Kana
Chan, Andrew T.
Cao, Yin
Song, Mingyang
Fuchs, Charles S.
Wang, Molin
Lennerz, Jochen K.
Ng, Kimmie
Meyerhardt, Jeffrey A.
Giannakis, Marios
Nowak, Jonathan A.
Ogino, Shuji https://orcid.org/0000-0002-3909-2323
-
Funding
Funding for this research was provided by:
National Institutes of Health (P01 CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, U01 CA167552, P50 CA127003, R01 CA118553, R01 CA169141, R01 CA137178, K24 DK098311, R35 CA197735, R01 CA151993, R01 CA248857, R01 CA225655)
National Institutes of Health (K07 CA188126)
Cancer Research UK’s Grand Challenge Initiative (UK C10674/A27140)
Dana-Farber/Harvard Cancer Center
American Association for Cancer Research (SU2C-AACR-DT22-17)
Uehara Memorial Foundation
Yasuda Memorial Medical Foundation
Japan Society for the Promotion of Science
National Colorectal Cancer Research Alliance and SU2C
- License Information
-
More Information
Article History
Received: 13 March 2021
Accepted: 7 September 2021
First Online: 16 September 2021
Declarations
:
: J.A.M. has received institutional research funding from Boston Biomedical, has served as an advisor/consultant to COTA Healthcare, and served on a grant review panel for the National Comprehensive Cancer Network funded by Taiho Pharmaceutical. M.G. receives research funding from Bristol-Myers Squibb, Merck, and Servier. This study was not funded by any of these commercial entities. A.T.C. previously served as a consultant for Bayer Healthcare and Pfizer Inc. This study was not funded by Bayer Healthcare or Pfizer Inc. C.S.F. is currently employed by Genentech, a subsidiary of Roche, and previously served as a consultant for Agios, Bain Capital, Bayer, Celgene, Dicerna, Five Prime Therapeutics, Gilead Sciences, Eli Lilly, Entrinsic Health, Genentech, KEW, Merck, Merrimack Pharmaceuticals, Pfizer Inc, Sanofi, Taiho, and Unum Therapeutics; C.S.F. also serves as a Director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health. No other conflicts of interest exist. The other authors declare that they have no conflicts of interest.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all study participants, and the study was approved by the institutional review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health (Boston, MA), and those of participating registries as required.
